Sites: CDL-Oxford, CDL-Seattle, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin
Streams: Advanced Therapies, Biomedical Engineering, Computational Health, Health & Wellness, Neuro
Dr. Milad Alucozai is a scientist, startup founder, and active investor with over two decades of experience in deep tech, primarily focusing on life sciences and technology commercialization. He is currently the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas fuelled by cutting-edge computational advances and engineering principles.
He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn, including Magic Pony (acquired by Twitter), Bloomsbury AI (acquired by Facebook), and many more. In 2020, he was appointed an External Advisor to AstraZeneca.
Dr. Alucozai is a recognized thought leader and mentor for entrepreneurs through the Creative Destruction Lab and Harvard University iLabs. He has worked with numerous companies, from founding through IPO or M&A, including Numerate, a San Francisco-based drug discovery company (acquired by Valo Health), and Absci, a Vancouver-based AI-powered synthetic biology company that recently went public.
He began his career as a bench scientist in translational neuroscience and multiphysics labs before transitioning into founding roles at multiple healthcare and bio startups. He is part of the founding team at Mekonos, a San Francisco-based company building a platform for cell delivery supporting the future of cell and gene therapies. Before this, he served on the founding team at Corstem, a company specializing in machine learning and artificial intelligence software (acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries). Thoma Bravo eventually acquired Circle for $213m. At Accenture, he led data scientists, designers, and engineers focused on building AI products for global pharmaceutical companies and hospital networks.
Dr. Alucozai is a former Visiting Scholar in Healthcare Engineering at the Regenstrief Center. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine and graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and subsequently his doctorate at the Richard M. Fairbanks School of Public Health.